• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Brain Metastasis - Pipeline Review, H2 2012 Product Image

Brain Metastasis - Pipeline Review, H2 2012

  • Published: August 2012
  • 146 Pages
  • Global Markets Direct

This report provides information on the therapeutic development for Brain Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Metastasis.

'Brain Metastasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Brain Metastasis.

- A review of the Brain Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline READ MORE >

2
List of Tables 4
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Brain Metastasis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Brain Metastasis 9
Brain Metastasis Therapeutics under Development by Companies 11
Brain Metastasis Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Brain Metastasis Therapeutics – Products under Development by Companies 19
Brain Metastasis Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Brain Metastasis Therapeutics Development 24
Abbott Laboratories 24
Sanofi-Aventis 25
YM BioSciences Inc. 26
Cell Therapeutics, Inc. 27
Geron Corporation 28
Spectrum Pharmaceuticals, Inc. 29
Philogen S.p.A. 30
to-BBB technologies BV 31
Brain Metastasis – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
OPAXIO - Drug Profile 38
Lucanthone - Drug Profile 40
GRN1005 - Drug Profile 42
ABT-888 - Drug Profile 44
Zolinza - Drug Profile 45
Temozolomide +Vinorelbine - Drug Profile 47
Lapatinib + Temozolomide - Drug Profile 48
Sorafenib - Drug Profile 49
Vorinostat + Radiation Therapy - Drug Profile 50
Bendamustine + Radiation Therapy - Drug Profile 52
Bendamustine + Radiation Therapy - Drug Profile 53
Carboplatin + Bevacizumab + Herceptin - Drug Profile 54
Lapatinib + Radiation Therapy - Drug Profile 55
Methotrexate + Liposomal Cytarabine - Drug Profile 56
memantine hydrochloride - Drug Profile 58
Gefitinib + Radiation Therapy - Drug Profile 59
Alimta - Drug Profile 60
Temozolomide - Drug Profile 61
Sutent - Drug Profile 63
Lapatinib + Whole Brain Radiation - Drug Profile 64
Depakene+ VePesid - Drug Profile 65
Temozolomide + Radiation Therapy - Drug Profile 66
BSI-201 + Irinotecan - Drug Profile 68
Temozolomide - Drug Profile 69
EMD121974 + Radiation Therapy - Drug Profile 71
Sutent - Drug Profile 72
Crixivan + Norvir + Radiation Therapy - Drug Profile 74
2B3-101 - Drug Profile 75
Temozolomide - Drug Profile 77
Erlotinib - Drug Profile 78
incyclinide - Drug Profile 79
Theracim + Radiation Therapy - Drug Profile 80
Erlotinib + Radiotherapy - Drug Profile 81
Ferumoxytol - Drug Profile 82
Erlotinib - Drug Profile 83
Irinotecan Hydrochloride + Radiation Therapy - Drug Profile 84
Temodar + Radiosurgery - Drug Profile 85
Iressa - Drug Profile 87
AZD2171 + Whole Brain Radiation - Drug Profile 89
Temodal - Drug Profile 90
polifeprosan 20 with carmustine implant - Drug Profile 91
everolimus + whole-brain radiation therapy - Drug Profile 92
Riluzole + Radiation Therapy - Drug Profile 93
Temozolomide - Drug Profile 94
Cilengitide - Drug Profile 96
EGb761 - Drug Profile 97
Epothilone B - Drug Profile 98
Irinotecan Hydrochloride - Drug Profile 99
RO4929097 + Radiation Therapy - Drug Profile 100
Lapatinib + Whole Brain Radiotherapy - Drug Profile 102
Bendamustine + Fractionated Stereotactic Radiotherapy - Drug Profile 103
Paclitaxel + Etoposide + Cisplatin + Radiotherapy - Drug Profile 105
RO4929097 + Capecitabine - Drug Profile 107
Temozolomide + Radiation Therapy - Drug Profile 109
Bevacizumab + Etoposide + Cisplatin - Drug Profile 110
Avastin + Brain Radiation Therapy - Drug Profile 112
Radretumab - Drug Profile 113
Gefitinib - Drug Profile 114
Gefitinib + Radiation Therapy - Drug Profile 115
Irinotecan + Temsirolimus - Drug Profile 116
Erlotinib + Pemetrexed + Cisplatin - Drug Profile 117
Vorinostat - Drug Profile 118
GRN-1005 + Herceptin - Drug Profile 119
Brain Metastasis Therapeutics – Drug Profile Updates 121
Brain Metastasis Therapeutics – Discontinued Products 127
Brain Metastasis Therapeutics - Dormant Products 128
Brain Metastasis – Product Development Milestones 131
Featured News & Press Releases 131
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 142
Disclaimer 142

List of Tables
Number of Products Under Development for Brain Metastasis, H2 2012 13
Products under Development for Brain Metastasis – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 27
Abbott Laboratories, H2 2012 28
Sanofi-Aventis, H2 2012 29
YM BioSciences Inc., H2 2012 30
Cell Therapeutics, Inc., H2 2012 31
Geron Corporation, H2 2012 32
Spectrum Pharmaceuticals, Inc., H2 2012 33
Philogen S.p.A., H2 2012 34
to-BBB technologies BV, H2 2012 35
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 41
Brain Metastasis Therapeutics – Drug Profile Updates 125
Brain Metastasis Therapeutics – Discontinued Products 131
Brain Metastasis Therapeutics – Dormant Products 132
Brain Metastasis Therapeutics – Dormant Products (Contd..1) 133
Brain Metastasis Therapeutics – Dormant Products (Contd..2) 134

List of Figures
Number of Products under Development for Brain Metastasis, H2 2012 13
Products under Development for Brain Metastasis – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Route of Administration, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Molecule Type, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 41

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos